within Pharmacolibrary.Drugs.ATC.D;

model D01AC02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.25,
    Cl             = 0.20833333333333334,
    adminDuration  = 600,
    adminMass      = 1.2,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Miconazole is an imidazole antifungal medication primarily used to treat superficial fungal infections, such as athlete's foot, ringworm, and candidiasis (including oral and vaginal candidiasis). It functions by inhibiting ergosterol synthesis, disrupting fungal cell membrane integrity. Miconazole is approved and widely used in topical, oral, and occasionally intravenous formulations for the treatment of fungal infections in various countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics in healthy adult volunteers following oral administration.</p><h4>References</h4><ol><li><p>Hynninen, VV, et al., &amp; Laine, K (2009). Oral voriconazole and miconazole oral gel produce comparable effects on the pharmacokinetics and pharmacodynamics of etoricoxib. <i>European journal of clinical pharmacology</i> 65(1) 89–95. DOI:<a href=&quot;https://doi.org/10.1007/s00228-008-0556-9&quot;>10.1007/s00228-008-0556-9</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/18777173/&quot;>https://pubmed.ncbi.nlm.nih.gov/18777173</a></p></li><li><p>Grönlund, J, et al., &amp; Laine, K (2011). Miconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4. <i>Antimicrobial agents and chemotherapy</i> 55(3) 1063–1067. DOI:<a href=&quot;https://doi.org/10.1128/AAC.01242-10&quot;>10.1128/AAC.01242-10</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/21173180/&quot;>https://pubmed.ncbi.nlm.nih.gov/21173180</a></p></li><li><p>Cardot, JM, et al., &amp; Aiache, JM (2004). Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. <i>British journal of clinical pharmacology</i> 58(4) 345–351. DOI:<a href=&quot;https://doi.org/10.1111/j.1365-2125.2004.02154.x&quot;>10.1111/j.1365-2125.2004.02154.x</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15373926/&quot;>https://pubmed.ncbi.nlm.nih.gov/15373926</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end D01AC02;
